Rightslink® by Copyright Clearance Center

Prognostic Importance of Measurable Residual Disease (MRD) Kinetics and Progression-Free Survival (PFS) Benefit in MRD+ Patients (Pts) with Ixazomib Vs Placebo As Post-Induction Maintenance Therapy: Results from the Multicenter, Double-Blind, Phase 3 TOURMALINE-MM4 Trial in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Pts

Author:

Bruno Paiva,Irene Manrique,Nicola Giuliani,Michele Cavo,Christine Rojas,Weijun Fu,María-Victoria Mateos,Meletios A Dimopoulos,Alexander Vorog,Cong Li,Bingxia Wang,Richard J Labotka,Ajeeta B Dash

Publication:

Blood

Publisher:

Elsevier

Date:

5 November 2020

Please select your organization and/or account

Organization

Account

Please select your account from the above dropdown list. These accounts represent the offices, campuses, and other sites where your organization operates. Your account selection should match where you typically have an office or workspace. Even when you are traveling or temporarily working elsewhere, you should select the account that represents where you customarily work.

Cancel OK

Content Excluded

This content has been excluded from the RightsLink's service. Please contact Elsevier directly with your request.